# Ultra Curto (Ultra Short) TB Prevention Therapy

> **NCT04703075** · PHASE4 · COMPLETED · sponsor: **Johns Hopkins University** · enrollment: 531 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **DRUG:** Rifapentine 600 mg and INH 300 mg
- **DRUG:** Rifapentine 900 mg and INH 900 mg

## Key facts

- **NCT ID:** NCT04703075
- **Lead sponsor:** Johns Hopkins University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-24
- **Primary completion:** 2024-06-10
- **Final completion:** 2024-06-10
- **Target enrollment:** 531 (ACTUAL)
- **Last updated:** 2025-06-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04703075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04703075, "Ultra Curto (Ultra Short) TB Prevention Therapy". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04703075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*